Optional to display an overview excerpt here…
Category: DIAN-TU Research Updates
The Knight Family DIAN-TU Primary Prevention Trial
Optional to display an overview excerpt here…
The Knight Family DIAN-TU Amyloid Removal Trial
Update to the 18 August 2023 announcement by the Knight Family DIAN-TU)regarding the DIAN-TU-001 Open Label Extension (OLE) Study
Update on the DIAN-TU-001 Gantenerumab Open Label Extension
This announcement is regarding the Knight Family DIAN-TU Open Label Extension (OLE) Study with gantenerumab (made by Roche and Genentech)
Update on the DIAN-TU-001 Open Label Extension with Gantenerumab (Roche/Genentech)
Questions and concerns from sites and participants regarding the status of the DIAN-TU-001 gantenerumab open label extension (OLE) study and next steps in the study.
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update on the DIAN-TU-002 Primary Prevention Trial
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
Response to the 14-November-2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
Response to the 28 September 2022 announcement found on Eisai’s website.
New eligibility criteria for participation in Tau NexGen E2814: A requirement for participants to learn their genetic status prior to enrollment
The new Tau NexGen E2814 clinical trial planned for DIAN-TU will be launching at most sites in 2022. This new trial design will offer individuals who have a dominantly inherited Alzheimer’s disease (DIAD) mutation access to investigational drugs that target both amyloid and tau. All participants will receive the anti-amyloid drug and also be randomized […]